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Abstract: Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer 
(NSCLC) is a particularly aggressive cancer, the optimum management of which is still being 
determined. In the metastatic disease, the standard therapy is a platinum-based combination 
chemotherapy; however, in spite of available treatment options for patients who progress beyond 
first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process which 
comprises a complex, complementary, and overlapping network. Inhibition of tumor-related 
angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy 
includes: monoclonal antibodies against vascular endothelial growth factor (VEGF) and VEGF 
receptor (VEGFR), small molecule inhibitors of VEGF tyrosine kinase activity, VEGF Trap, 
and a new class named “vascular disrupting agents,” tested in ongoing clinical trials which will 
further define their role in the management of NSCLC. BIBF 1120 is an investigational orally 
administered receptor tyrosine kinase inhibitor that has shown antiangiogenic and antineoplastic 
activity, inhibiting VEGFR, platelet-derived growth factor receptor, and fibroblast growth fac-
tor receptor tyrosine kinases, preventing tumor growth and interfering with the angiogenesis-
signaling cascade and overcoming drug resistances.
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Background
Non-small cell lung cancer (NSCLC) accounts for 85%–90% of all lung cancers1 with 
a median survival time of 7.0–8.3 months, and 1-year survival rates of 29%–37% who 
progress beyond first-line therapy, with an overall 5-year survival rate of only 15% 
in the metastatic disease.2
However, advances in the understanding of the biology of cancer have led to 
molecular targeted therapies. Tyrosine kinase inhibitors (TKIs) are the largest class 
of therapeutic agents in clinical use and under development that target angiogenesis.
Angiogenesis and neovascularization are critical for the growth, progression, and 
metastasis of solid tumors, including NSCLCs,3–5 so angiogenic pathways have become 
an important biologic target to inhibit tumor growth. Several pathways for vascular-
ity and tumor neoangiogenesis have been identified, including vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth 
factor (PDGF) pathways.5,6
The VEGF pathway is critical to tumor angiogenesis and has become an important 
therapeutic target. The VEGF family consists of five glycoproteins (VEGF-A through 
VEGF-D and placental growth factor), which act by binding to their cognate tyrosine 
kinase receptor (VEGF receptor [VEGFR]).
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Given their central role in angiogenesis,   monoclonal 
  antibodies against VEGF and TKIs directed towards 
  VEGFRs have been developed.6,7
The FGF family of ligands comprises a number of 
growth factors with a broad spectrum of activity, including 
angiogenic activity.8,9 One such ligand, FGF-2, has been 
detected in high levels in patients with highly vascularized 
tumors, and its expression has been correlated with cancer 
progression and metastatic disease.9 The PDGF pathway 
has also demonstrated angiogenic activity by way of recruit-
ing pericytes and vascular smooth muscle cells, which are 
critical to the maturation of newly developing vasculature.10 
Studies suggest that FGF and PDGF may act synergistically 
to promote angiogenesis by reciprocally enhancing their 
activities on endothelial cells, pericytes, and vascular smooth 
muscle cells.9,10
BIBF 1120 (Vargatef™, Boehringer Ingelheim, Ingelheim, 
Germany) is an indolinone derivative potently blocking 
  VEGFRs, PDGF receptors (PDGFRs) and FGF receptor 
(FGFR) kinase activity in enzymatic assays (half-maximal 
inhibitory concentration [IC50], 20–100 nmol/L). It also 
inhibits mitogen-activated protein kinase (MAPK) and Akt 
signaling pathways in endothelial cells, pericytes, and smooth 
muscle cells, resulting in inhibition of cell proliferation 
  (half-maximal effective concentration [EC50], 10–80 nmol/L) 
and apoptosis. In all tumor models tested, BIBF 1120 is highly 
active at well tolerated doses (25–100 mg/kg daily, orally).
Antiangiogenic TKIs in NSCLC
Sorafenib
Sorafenib is an oral TKI with multiple targets, including 
VEGFR, PDGFR, RAF, c-KIT, rearranged during transfection 
(RET), and fms-like tyrosine kinase (FLT)-3.11,12 It has been 
approved by the United States Food and Drug Administration 
(FDA) as a single agent in the treatment of advanced renal 
cell carcinoma (RCC) and hepatocellular carcinoma,13 and in 
preclinical models it also shows dose-dependent antitumor 
activity in NSCLC, either when administered alone or in com-
bination with other chemotherapy agents such as vinorelbine 
and cisplatin and with targeted agents such as gefitinib.14
Based on Phase I trials that included patients with 
NSCLC, the recommended dose of sorafenib for Phase II 
studies is 400 mg twice daily, given orally.15
As a single agent in two Phase II studies, sorafenib shows 
an advantage either in progression-free survival (PFS) and in 
overall survival (OS) with respect to placebo; rash/hand-foot 
reactions, fatigue, hypertension, and diarrhea were the most 
common grade 3/4 toxicities.16,17
After a Phase I/II trial where sorafenib combined with 
carboplatin and paclitaxel showed a median PFS of 34 weeks 
with a good toxicity profile,18 two Phase III trials were con-
ducted to confirm the efficacy and feasibility of the combina-
tion treatment: the ESCAPE trial, with carboplatin paclitaxel; 
and the NEXUS trial, with gemcitabine/cisplatin.
Unfortunately neither of the trials met their primary 
  endpoints: the ESCAPE trial was terminated early due the 
futility at interim analysis without any advantage in OS or 
disease control rate (DCR) and there was reported a higher 
rate of grade 5 drug-related adverse events (AEs) with 
sorafenib in patients with squamous cell histology;19 and in 
the NEXUS (NCT00449033) trial, conducted exclusively in 
patients with nonsquamous NSCLC, sorafenib plus chemo-
therapy didn’t improve OS.20
Another interesting combination studied was with agents 
that target the EGF, assuming that the possibility to overcome 
resistance to epidermal growth factor receptor (EGFR) TKIs 
in patients whose tumors express K-Ras mutations, or that 
simultaneous inhibition of both pathways (VEGF and EGF) 
may prove to be additive or synergistic.21,22
In a Phase II trial, sorafenib combined with erlotinib as 
first-line therapy met the primary endpoint with a rate of 
nonprogression at 6 weeks of 74%: 12 (24%) partial response 
(PR) and 25 (50%) stabilization of disease (SD). Patients 
with wild-type EGFR had a higher objective response rate 
(ORR) (19%) than previously reported for single-agent 
erlotinib/sorafenib.23
Another Phase II trial, which randomized patients into 
one of four treatments (erlotinib, sorafenib, vandetanib, and 
erlotinib plus bexarotene), based on biomarker status, showed 
in the sorafenib arm a DCR of 58% (57 in 98 patients) but 
a higher DCR (61%, 11/18) in K-RAS-mutated patients, in 
contrast to 31% (4/13) in K-RAS-mutated patients treated 
with erlotinib regimen.24
The authors of this paper, as monotherapy, have a large 
ongoing multicenter, Phase III, third/fourth-line placebo-
controlled trial of sorafenib in patients with predominantly 
nonsquamous NSCLC (MISSION trial) planned to determine 
whether sorafenib plus best supportive care is an effective 
treatment for lung cancer compared with best supportive 
care alone. The estimated enrolment is 850 patients, and 
the primary endpoint of this study is OS.
Sunitinib
Sunitinib is another multitargeted oral TKI; it targets   VEGFR-2, 
PDGFR, FGFR, FLT-3, RET, and c-KIT,25,26 approved by 
the FDA as a single agent for the treatment of patients who 
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have advanced RCC and for patients with imatinib-resistant 
  or -intolerant gastrointestinal stromal tumors.27
In NSCLC, sunitinib has been studied as a single agent 
in two dosing schedules: continuous and intermittent. 
A Phase II study examined the role of continuous daily   dosing 
(CDD) sunitinib 37.5 mg in 47 previously treated patients with 
advanced NSCLC, with 2.1% PR, 23.4% SD, while the median 
PFS and OS were 11.9 weeks and 37.1 weeks, respectively.26 
A second Phase II study evaluated a different dosing schedule: 
sunitinib 50 mg/d for 4 weeks followed by a 2-week break. PRs 
were observed in seven patients (ORR, 11.1%; 95% confidence 
interval [CI], 4.6%–21.6%); SD for $8 weeks was observed 
in 18 patients (28.6%). The median PFS was 12.0 weeks (95% 
CI, 10.0–16.1 weeks) with a median OS of 23.4 weeks (95% 
CI, 17.0–28.3).27 Both   studies reported fatigue, hypertension, 
dyspnea, and bleeding.
Data with sunitinib in combination with chemotherapy 
are limited. In a Phase I dose-escalation study, sunitinib in 
combination with cispatin/gemcitabine as first-line advanced 
NSCLC therapy, the maximum tolerated dose (MTD) was 
identified as sunitinib 37.5 mg (schedule 2/1), gemcitabine 
1250 mg/m2, and cisplatin 80 mg/m2, showing an antitumor 
activity with a manageable toxicity profile,28 as well as in 
another Phase I in combination with docetaxel (75 mg/m2), 
in several advanced solid tumors including NSCLC.29
As in the case of sorafenib, sunitinib has been evaluated 
in combination with EGFR inhibitor, erlotinib, in a double-
blind Phase II study, in patients with platinum refractory 
NSCLC: patients are randomized to erlotinib alone versus 
the combination of erlotinib plus sunitinib in the second-line 
treatment.
Diarrhea and fatigue are the most frequent grade 3/4 
  toxicities, with no erlotinib interaction on sunitinib: two 
patients had a durable PR and two patients reported SD for 
16 weeks. The Phase II portion of this trial is ongoing.30
A Phase III randomized, multicenter clinical trial 
(SUN1087) will evaluate the combination of erlotinib at 
standard dose plus sunitinib at CDD versus erlotinib plus 
placebo given in 4-week cycles in 956 advanced NSCLC, 
which have received one or two chemotherapy regimens 
including platinum-based therapy.31
Vandetanib
Vandetanib (ZD6474) is a novel, orally available, adenosine-
5-triphosphate (ATP)-mimetic small molecule targeting 
VEGFR-2, EGFR, and RET tyrosine kinase,32 and blocks 
multiple intracellular signaling pathways involved in tumor 
growth, progression, and angiogenesis.33
In a Phase I trial, single-agent vandetanib was well 
  tolerated in a variety of solid tumors at 300 mg daily,31 so 
in a randomized double-blind Phase II trial it was compared 
with gefitinib at standard dose, as a first-line treatment, 
with a crossover design: OS was similar between these two 
arms but the crossover should be a confounder. The most 
  common AEs relating to vandetanib were diarrhea, rash, 
and asymptomatic QTc (QT interval corrected for heart 
rate) prolongation.34
In other Phase II trials, vandetanib (100 or 300 mg daily) 
was evaluated in combination with docetaxel (75 mg/m2 
3-weekly) as second-line treatment for advanced or metastatic 
NSCLC patients,37 or with carboplatin plus paclitaxel38 in 
first line. Both studies demonstrated a prolonged PFS, but 
without any advantage in OS.35,36
The ZODIAC and the ZEAL, two randomized, double-
blind Phase III trials, compared vandetanib 100 mg plus 
docetaxel or pemetrexed to docetaxel or pemetrexed alone, 
respectively: while the first combination showed an improve-
ment in median PFS with a positive trend, but not statistically 
significant, in OS,37 the combination with pemetrexed didn’t 
meet the first endpoint, the PFS.38
In a Phase III trial (Zactima Efficiacy when Studied 
versus Tarceva [ZEST]), vandetanib versus erlotinib was 
evaluated in 1240 pretreated patients with advanced NSCLC; 
vandetanib did not prolong PFS or increase ORR, but there 
was a higher incidence of diarrhea and hypertension in the 
vandetanib group, whereas skin rash was more common in 
the erlotinib arm.39
In the ZEPHYR (Zactima Efficacy trial for NSCLC 
Patients with History of EGFR-TKI and chemo-Resistance) 
trial, a Phase III, randomized, double-blind, multicenter study 
that evaluated the efficacy of vandetanib plus best support-
ive care (BSC) versus BSC alone in patients with advanced 
NSCLC after failure of prior therapy with an EGFR inhibitor. 
The primary endpoint of a superior OS for patients receiving 
vandetanib was not met. However, significant advantages 
favoring vandetanib were observed for the PFS (hazard ratio 
0.63; 95.2% CI 0.54–0.74; P , 0.0001), response rate (RR) 
(2.6% versus 0.7%; P = 0.028), and DCR at 8 weeks (30% 
versus 16%; P , 0.0001).40
Cediranib
Cediranib (AZD2171) targets VEGFR, c-KIT, and PDGFR 
signaling.41,42 Two Phase I studies have evaluated cediranib 
(30 or 45 mg) in combination respectively with carboplatin 
area under the curve (AUC) 6 and paclitaxel 200 mg/m2 or 
with cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2, with no 
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dose-limiting   toxicities during the first cycle with both doses. 
There was a good DCR, and the recommended Phase II/III 
dose of cediranib was 30 mg/d, with fatigue, nausea, diarrhea, 
anorexia, and hypertension the most common toxicities.43,44
After the failure in the BR.24 trial, where cediranib 
30 mg/d combined with carboplatin/paclitaxel or placebo 
improved RR but not median PFS, and with a high toxicity 
profile,45 in the BR.29 trial (NCT00795340) cediranib was 
evaluated at a lower dosage (20 mg/d) combined with the 
same chemotherapeutic regimen versus chemotherapy plus 
placebo as first-line treatment in advanced NSCLC.
Currently, two Phase II studies are accruing patients: 
cediranib combined with pemetrexed or in combination 
with carboplatin plus paclitaxel. Preliminary results haven’t 
shown any significant improvement in PFS, OS, or RR with 
the addition of cediranib as first-line therapy in previously 
untreated patients with NSCLC.46,47
Axitinib
Axitinib (AG-013736) is an orally bio-available TKI that 
targets VEGFR, PDGFR, and colony-stimulating factor-1 
receptor,48 inhibiting the pro-angiogenic VEGF-1, -2, and -3 
and PDGFRs inhibiting angiogenesis, vascular permeability, 
and blood flow in a wide range of tumor types.49
In a Phase I trial (N = 47), axitinib combined with car-
boplatin plus paclitaxel in patients previously untreated, or 
cisplatin plus gemcitabine in patients who received prior 
treatment for metastatic disease, the determined MTD was 
axitinib 5 mg twice a day (bid). Most common toxicities were 
fatigue, hypertension, headache, and diarrhea,50 with strong 
evidence of clinical activity.51
An open-label, multicenter Phase II study evaluated the 
efficacy and safety of axitinib in advanced NSCLC patients 
previously treated with chemotherapy and/or radiotherapy. The 
majority of patients (75%) had adenocarcinoma, with a good 
DCR and an OS similar in patients receiving axitinib as a single 
agent in first-line therapy, with a good toxicity profile.52
Pazopanib
Pazopanib is a potent and selective multitargeted   receptor 
TKI of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α and 
PDGFR-β, and c-KIT that blocks tumor growth and inhib-
its angiogenesis. Pazopanib is currently being studied in a 
  number of different tumor types, and clinical trials are ongo-
ing in RCC, breast cancer, ovarian cancer, soft tissue   sarcoma, 
NSCLC, cervical cancer, and other solid tumors.53
In a Phase I trial, patients with advanced-stage refractory 
solid tumors including NSCLC were enrolled into   sequential 
dose-escalating cohorts of axitinib (50 mg three times 
weekly to 2000 mg once daily and 300–400 mg twice daily). 
A monotherapy dose of 800 mg once daily was selected for 
Phase II studies.54 The most frequent drug-related AEs were 
hypertension, diarrhea, hair depigmentation, and nausea, the 
majority of which were of grade 1/2.
Interestingly, early Phase II data for stage IA to IIA 
NSCLC have been reported in the neo-adjuvant setting 
for this agent,55 at 800 mg/d for 2–6 weeks before surgery. 
Among 35 patients enrolled, three PRs were observed. 
  Significant toxicities included pneumonia, rash, urinary tract 
infection, blood potassium elevation, lymphopenia, dyspnea, 
and transaminase elevation (all grade 3).56 Based on these 
promising data, further studies with pazopanib in multiple 
stages of NSCLC are planned.
Motesanib
Motesanib (AMG 706) is a small oral, multikinase   inhibitor, 
molecule antagonist of VEGFR-1, -2, and -3, PDGFR, KIT, and 
RET. Preclinical studies demonstrated inhibition of VEGF-in-
duced angiogenesis and inhibition of tumor growth in vivo.57
In a Phase Ib study, motesanib was combined with 
carboplatin plus paclitaxel showing the same RR as the same 
regimen plus panitumumab (17%) in advanced NSCLC. 
In another arm of this study motesanib was combined with 
panitumumab showing no benefit in terms of RR.   Common 
motesanib-related AEs observed were fatigue (60% of 
patients), diarrhea (53%), hypertension (38%), anorexia (27%), 
and nausea (22%).58
On this basis a phase II trial was organized where 
181 patients were randomly assigned to three treatment arms: 
paclitaxel/carboplatin for 6 cycles maximum plus motesanib, 
continuously or intermittent orally, versus the same chemo-
therapic regimen plus bevacizumab: motesanib continuously 
assumed plus carboplatin/paclitaxel had ORR median PFS 
and OS similar to carboplatin/paclitaxel plus bevacizumab. 
The most common all-grade toxicities included cholecystitis, 
hemorrhagic events, deep vein thrombosis, and pulmonary 
embolism (3%, 2%, 3%).59
A Phase III, multicenter, randomized, placebo-controlled, 
double-blind trial (MONET-1) is ongoing to evaluate the 
addition of motesanib to paclitaxel and carboplatin com-
pared with the same chemotherapy regimen plus placebo in 
advanced NSCLC patients. Since November 2008, subjects 
were excluded from the enrolment because of a higher rate 
of early mortality rate and incidence of hemoptysis in the 
motesanib group compared with the placebo group in the 
squamous population.60
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BIBF 1120
BIBF 1120, an orally administered indolinone   derivative, 
is a novel, potent, triple angiokinase inhibitor, which 
simultaneously acts on three key receptor families involved 
in angiogenesis: VEGFR, FGFR, and PDGFR-α and -β. 
BIBF 1120 competitively binds to the ATP-binding site of 
receptor tyrosine kinases and inhibits downstream intracel-
lular   signaling. Biochemical assays demonstrate that BIBF 
1120 inhibits a narrow range of kinases at pharmacologically 
relevant concentrations: VEGFR types 1, 2, and 3, PDGFR-α 
and PDGFR-β, FGFR types 1, 2, and 3, FLT-3, and members 
of the Src family61 (Figure 1). Inhibition of these receptors 
found on endothelial cells, tumor cells, and pericytes allows 
BIBF 1120 to potentially prevent both tumor growth and dis-
semination, and also provides a possible solution to intrinsic 
and acquired resistance observed with other single or dual 
angiogenesis inhibitors.63
Moreover, BIBF 1120 has a sustained duration of cellular 
action blocking, with 50 nmol/L BIBF 1120; the in-vitro auto-
phosphorylation of VEGFR-2 for around 32 hours62 indicates 
the potential for a long-lasting antiangiogenic effect.
Clinical studies demonstrate maximum BIBF 1120 
plasma concentrations occurred mainly 1–4 hours after 
oral administration.63 No deviation from dose propor-
tionality in the pharmacokinetics of BIBF 1120 has been 
observed. BIBF 1120 showed a high   apparent volume of 
distribution during the terminal phase, both after single 
dose and at steady state, which might indicate a high tissue 
distribution of the drug. In addition, there was no decrease 
in exposure over time during continuous daily treatment 
with BIBF 1120.
From clinical investigation, the cleavage of [14C]BIBF 
1120 by esterase-catalyzed hydrolysis is the prevalent 
metabolic reaction; cytochrome P450 (CYP450)-dependent 
metabolism was found to be minor. The terminal half-life 
of BIBF 1120 was determined to be 19 hours. BIBF 1120 is 
mainly excreted via the liver (Table 1).
Pharmacodynamic and pharmacokinetic profile
BIBF 1120 binds to the ATP-binding site in the cleft between 
the NH2 and the COOH terminal lobes of the kinase domain. It 
inhibits targeted kinases including all three VEGFR subtypes 
(IC50, 13–34 nmol/L), PDGFR-α and PDGFR-β (IC50, 59 and 
65 nmol/L), and FGFR types 1, 2, and 3 (IC50, 69, 37, and 
108 nmol/L, respectively); as well as in corresponding human 
and rodent kinases. In addition, BIBF 1120 inhibits FLT-3 
(inhibition of acute myelogenous leukemia cell proliferation), 
and members of the Src-family (Src, Lyn, and Lck).
By contrast, receptor tyrosine kinases, such as EGFR 
and HER2, InsR, IGF-IR, or the cell cycle kinases CDK1, 
CDK2, and CDK4 were not inhibited at concentrations below 
1000 nmol/L.
After oral administration, maximum BIBF 1120 
plasma concentrations occurred mainly 1–4 hours after 
  administration.61 BIBF 1120 showed a high apparent 
volume of distribution during the terminal phase, both 
after single dose and at steady state, which might indicate 
a high tissue distribution of the drug, without any decrease 
in exposure over time during continuous daily treatment 
with BIBF 1120. From clinical investigation, the cleavage 
of [14C]BIBF 1120 by esterase-catalyzed hydrolysis is the 
prevalent metabolic reaction; CYP450-dependent metabo-
lism was found to be minor. The terminal half-life of BIBF 
1120 was determined to be 19 hours. BIBF 1120 is mainly 
excreted via the liver.
In the Hilberg experiment, the inhibition of cell pro-
liferation and apoptosis of endothelial cells derived from 
umbilical veins (HUVEC) and skin micro-vessels (HSMEC) 
was obtained with BIBF 1120 (EC50, ,10 nmol/L) and was 
preceded by inhibition of MAPK and Akt phosphorylation. 
Inhibition of basic-FGF-stimulated HUVEC proliferation 
required higher drug concentrations (EC50, 290 nmol/L), 
although activation of both MAPK and Akt was at least 
partially suppressed at concentrations down to 100 nmol/L. 
On the pericytes, BIBF 1120 inhibited proliferation of 
PDGF-BB-stimulated bovine retinal pericytes with an EC50 
of 79 nmol/L. In cultures of human vascular smooth muscle 
cells, BIBF 1120 blocks the activation of MAPK or of Akt 
at concentrations down to 100 nmol/L.
VEGFs
FGFs
PDGFs
Endothelial cells
VEGFRs, FGFRs
Pericytes
PDGFRs
Smooth muscle cells
FGFRs, PDGFRs
Ligands StimulationC ell type/receptors
Figure 1 Triple mechanism of action of BIBF-1120: it inhibits all three VEGFR 
subtypes, PDGFR-α and PDGFR-β and FGFR types 1, 2, and 3. Other targets of this 
drug are the FLT-3 (inhibition of acute myelogenous leukemia cell proliferation), and 
members of the Src-family (Src, Lyn, and Lck). 
Abbreviations: FGF, fibroblast growth factor; FGFR, FGF receptor; FLT-3, fms-like 
tyrosine kinase 3; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; 
VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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Clinical efficacy
Due to its unique triple-targeting profile, the potential of 
BIBF 1120 to prevent both tumor growth and dissemination 
while also avoiding problems such as redundancy or resis-
tance in advanced solid tumors was investigated.
Phase I
Based on several Phase I, BIBF 1120 monotherapy, dose-
escalation trials, the MTD of BIBF 1120 was defined 
as 250 mg bid in Caucasian patients and 200 mg bid in 
Japanese patients64,65 divided into two daily administrations 
more tolerable and without additional toxicity. The most 
frequent AEs were nausea, diarrhea, vomiting, abdominal 
pain, and fatigue of a mild-to-moderate intensity. Occasion-
ally grade 3 or 4 reversible liver enzyme elevations (alanine 
amino-transferase and aspartate-amino-transferase) were 
observed, without any drug-related bleeding events.
Furthermore, Phase I dose-escalation studies investigat-
ing BIBF 1120 in combination with standard chemotherapy 
regimens have also been conducted. One study investigated 
the MTD of continuous oral treatment with BIBF 1120 in 
combination with standard-dose pemetrexed (500 mg/m2) in 
patients with recurrent NSCLC who had been treated with 
one prior platinum-based chemotherapy regimen,66 while a 
second study investigated the safety, tolerability, and MTD 
of BIBF 1120 in combination with carboplatin (AUC 6) and 
paclitaxel (200 mg/m2) in previously untreated patients with 
advanced-stage (IIIB/IV) NSCLC.67
The recommended dose of BIBF 1120 was maintained to 
be 200 mg bid even when combined with standard regimens 
for NSCLC; they obtained a good safety profile, with high 
tolerability and an optimal pharmacokinetic effect of BIBF 
1120 when used in combined with standard chemotherapy. 
The AE profiles observed were comparable to those in the 
BIBF 1120 monotherapy trials, except for toxicities com-
monly related to the chemotherapy agent.
Promising efficacy effect was shown in both studies, but 
especially in the pemetrexed one: they enrolled 31 patients, 
and 26 received the treatment. Of the 26 patients treated, 
21 completed the initial 21-day treatment cycle and were 
eligible to continue in the second one and beyond. Thirteen 
patients (50%) had stable disease as the best overall response, 
while eight patients showed progressive disease as best 
response; three patients had missed follow-up radiology data 
due to early treatment termination. Nine patients completed 
four cycles of combination therapy, and seven patients went 
on to receive BIBF 1120 monotherapy. One patient with a 
complete response obtained after 44 days after initiating 
treatment completed the study and has remained on 100 mg 
bid BIBF 1120 monotherapy for more than 3 years.
The most common reasons for study discontinuation were 
disease progression (57.7%) and dose-limiting   toxicities 
(19.2%). Median PFS for all 26 treated patients was approxi-
mately 5.4 months.
Furthermore, dynamic contrast enhanced magnetic reso-
nance imaging results demonstrated an antiangiogenic effect 
of BIBF 1120 in a substantial number of patients.
Phase II
The key Phase II evidence for BIBF 1120 in NSCLC has been 
obtained from a double-blind, two-arm, randomized mono-
therapy study68,69 in patients with relapsed, advanced NSCLC 
of any histology. The primary endpoints were PFS and ORR.
Secondary endpoints included characterization of the safety 
and pharmacokinetic profiles of BIBF 1120, as well as OS.
A total of 73 patients were randomized with an Eastern 
Cooperative Oncology Group (ECOG) performance   status 
(PS) 0–2 with locally advanced or metastatic relapsed NSCLC 
Table 1 Kinase inhibition: comparing BIBF 1120 with other small-molecule VEGFR inhibitors
Drug Half-life (h) IC50(nM)
VEGFR1 VEGFR2 VEGFR3 PDGFR α/β FGFR1/3 KIT EGFR
Sunitinib 44 15 38 30 69/65 675 10 NR
Sorafenib ∼27 NR 90 20 NR/57 580 68 .10,000
Vandetanib ∼120 1600 40 110 NR/1100 3600 .20,000 500
Cediranib 13–25 5 ,1 ,3 36/5 26 2 .1000
AMG 706 5–7 2 3 6 84 .2800 8 .3000
Axitinib 2–5 1.2 0.25 0.29 2/NR 230 NR NR
Vatalanib 3–6 54 39 195 567 NR 364 NR
BIBF 1120* 7–19 34 21 13 59/65 69/108 NR .50,000
Note: *Biochemical IC50 values were determined using slightly different methods between the studies and are not directly comparable. 
Abbreviations: EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; IC50, half-maximal inhibitory concentration; PDGFR, platelet-derived 
growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
434
Gori et alTherapeutics and Clinical Risk Management 2011:7
Gender
70
60
50
40
30
20
10
0
70
80
90
60
50
40
30
20
10
0
70
80
60
50
40
30
20
10
0
Male Female IIIB IV 2 0/1 23 1
Squamous cell
Adenocarcinoma
Large cell
Other
F
r
e
q
u
e
n
c
y
 
(
%
)
Location of metastatic site Number of previous
chemotherapies
Histology ECOG Stage
60
50
40
30
20
10
0
Lung
Liver
Adrenal gland
Pleura
Bone LN
Brain
Other location
60
70
50
40
30
20
10
0
60
70
50
40
30
20
10
0
Figure 2 Demographic distribution of population from a Phase II randomized double-blind study with BIBF 1120 as monotherapy in advanced non-small cell lung cancer.
Abbreviations: ECOG, Eastern Cooperative Oncology Group score; LN, lymph node.
after failure of first- or second-line chemotherapy to continu-
ous twice-daily treatment with 150 (37 patients) or 250 mg 
(36 patients) BIBF 1120 until disease progression (Figure 2).
The median PFS of all patients (n = 73) was 6.9 weeks, 
and the median OS was 21.9 weeks with no significant dif-
ference between the two groups; the DCR was 59%. One PR 
was observed in the 250 mg bid arm, with a 74% reduction 
in tumor size for up to 9 months; 20 patients showed tumor 
shrinkage as best response, and the stable disease rate was 
48%. Stratifying patients for PS, an ECOG PS 0–1 (n = 57) 
had a median PFS of 2.9 months, with a median OS of 
9.5 months. Three patients maintained clinical benefit for 
more than 1 year, and four patients achieved a maximum 
decrease of at least 25% in tumor size (Figure 3).
With respect to physical functioning and global health 
status, 67.8% and 82.1% of all patients remained stable or 
showed an improvement within the first 42 days as measured 
by the European Organisation for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30. 
More than 50% of patients reported stable or improved cough, 
dyspnea, and pain on day 42 (87.5%, 58.9%, and 57.1% for 
each symptom, respectively) as measured by the EORTC 
QLQ-LC13. Twenty-two percent of patients discontinued 
before day 42 (19% and 26% for the 150 and 250 mg BIBF 
1120 bid dose cohorts, respectively).
The majority of AEs reported were mild to moderate 
in nature and predominantly related to the gastrointestinal 
tract (nausea, diarrhea, and vomiting). Severe drug-related 
  bleeding and hypertension were not observed, and there were 
no major differences in toxicity with regards to histology.
The BIBF 1120 tolerability was comparable between the 
two doses, with the exception of a higher frequency of liver 
enzyme elevations in the higher dose group (Table 2).
Steady state was reached by day 15 for both groups. The 
BIBF 1120 pre-dose plasma concentrations on days 15, 29, 
and 43 were stable during all this period for both doses, with 
no deviation from dose proportionality. Moderate-to-high 
inter-patient variability of BIBF 1120 pre-dose plasma con-
centrations was observed. In both arms, BIBF 1120 plasma 
concentrations increased within the first 3 hours after the first 
drug administration. There was only slight accumulation of 
BIBF 1120 plasma concentrations from day 1 to day 43 for 
both dose groups.
These Phase II data confirmed the promising single-agent 
activity of BIBF 1120 in patients suffering from recurrent 
NSCLC, warranting further development of BIBF 1120 in 
the Phase III setting.
Phase III development program
The BIBF 1120 Phase III clinical development program is 
currently underway, with patients being recruited into two 
pivotal studies, LUME-Lung 1 and 2. The LUME-Lung study 
program is investigating the potential benefit of adding BIBF 
1120 to standard chemotherapy in patients with advanced 
NSCLC in the second-line setting. Based on the overall safety 
profile from Phase I and II investigations, BIBF 1120 200 mg 
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bid is the recommended Phase III dose for a combination 
of BIBF 1120 with pemetrexed and docetaxel. Besides the 
primary endpoint of PFS, both trials are statistically powered 
to give adequate information on OS (Figure 4).
LUME-Lung 1 is a multicenter, randomized (1:1), 
  double-blind study to investigate the efficacy and safety 
of BIBF 1120 200 mg bid plus standard docetaxel therapy 
compared with placebo plus standard docetaxel therapy in 
patients with stage IIIB/IV or recurrent NSCLC (all his-
tologies) after relapse or failure of first-line chemotherapy.70 
Patients continue in 21-day treatment cycles upon completion 
of a minimum of four courses of combination therapy, or as 
long as they tolerate therapy or do not develop progression 
and do not meet one of the withdrawal criteria; patients who 
are ineligible for further combination therapy can continue 
to receive BIBF 1120/placebo monotherapy until disease 
progression or withdrawal criteria are met. The primary 
endpoint of the study is the PFS, while secondary endpoints 
are: OS, tumor response according to modified Response 
Evaluation Criteria In Solid Tumors (RECIST) criteria, clini-
cal improvement, AEs (according to Common Terminology 
Criteria for Adverse Events [CTCAE] version 3.0), changes 
in safety laboratory parameters, and quality of life.
LUME-Lung 2 is a multicenter, randomized, double-blind 
study to investigate the efficacy and safety of BIBF 1120 
200 mg bid plus standard pemetrexed therapy compared 
with placebo plus standard pemetrexed therapy in patients 
with stage IIIB/IV or recurrent nonsquamous NSCLC after 
relapse or failure of first-line chemotherapy.71 The trial will 
be carried out by investigators who specialize in the treatment 
of NSCLC. Written informed consent will be obtained prior 
to randomization.
A total of 1300 patients will be enrolled, with each arm 
containing 650 patients. Patients will be assigned to receive 
either: pemetrexed (500 mg/m2 intravenously on day 1) and 
BIBF 1120 (200 mg twice daily) on days 2–21 of each 21-day 
cycle, or pemetrexed on day 1 plus placebo twice daily on 
days 2–21 of each 21-day cycle.
The primary endpoint will be PFS. Secondary end-
points include objective tumor response (at baseline and 
every 6 weeks) assessed according to modified RECIST 
criteria and OS.73 Safety will be evaluated using CTCAE 
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Figure 3 Demographic distribution by overall clinical response status from Phase II randomized double-blind study with BIBF 1120 as monotherapy in advanced non-small 
cell lung cancer. 
Abbreviation: ECOG, Eastern Cooperative Oncology Group score.
Table 2 Most frequent adverse events linked to different doses 
of BIBF 1120 as monotherapy from Phase II randomized double-
blind study in advanced non-small cell lung cancer
Grade 3 CTCAE, % Grade 4 CTCAE, %
150 mg  
bid
250 mg  
bid
150 mg  
bid
250 mg   
bid
Nausea 2.7 11.1 0 0
Vomiting 2.7 5.6 0 0
Diarrhea 5.4 11.1 0 0
Fatigue 0 2.8 0 0
Abdominal pain 0 5.6 0 0
ALT increase 0 19.4 0 0
AST increase 0 2.8 0 0
GI bleeding 0 0 0 0
Hemoptysis 0 0 0 0
GI perforation 0 0 0 0
Hypertension 0 0 0 0
Dizziness 2.7 0 0 0
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
bid, twice daily; CTCAE, Common Terminology Criteria for Adverse Events.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
436
Gori et alTherapeutics and Clinical Risk Management 2011:7
  version 3.0. Quality of life will be measured with various self-
assessment questionnaires, including the EuroQoL EQ-5D, 
EORTC QLQ-C30, and EORTC QLQ-LC13. Patients will 
be treated until unacceptable toxicity or disease progression 
occurs or until another withdrawal criterion is met. Patients 
who discontinue combination therapy due to toxicity with 
either pemetrexed or BIBF 1120 and have not developed 
disease progression may continue with either blinded BIBF 
1120 monotherapy, pemetrexed monotherapy, or placebo if 
they received at least 4 cycles of combination therapy and 
have not fulfilled any of the withdrawal criteria. If less than 
4 cycles of combination therapy were received, patients 
may continue pemetrexed monotherapy. These patients will 
continue on treatment until disease progression or one of the 
other withdrawal criteria is met. These studies are currently 
ongoing.
Conclusion
Tumor angiogenesis remains a critical target for the treat-
ment of patients with NSCLC. Multiple mechanisms are 
responsible for this aspect of tumor growth and, as a result, 
several approaches to treatment are necessary. A number of 
antiangiogenic TKIs currently under development may provide 
additional treatment options for patients in the future. Research 
continues to reveal novel pathways and targets. As oncologists 
strive to improve patients’ lives, toxicity remains an important 
consideration. Ongoing Phase III trials will bring into focus the 
changing role of these agents for patients with NSCLC.
BIBF 1120 differs from other angiogenesis inhibi-
tors not only in its distinctive VEGFR-, PDGFR-, and 
FGFR-targeting profile, but also with regard to its sustained 
cellular duration of action and its pharmacokinetic profile.
Assuming its convenient oral application and good toler-
ability, no severe bleeding, skin reactions, hypertension, or 
hematological side effects are observed in patients suffering 
from all histologies.
In Phase II trials, the predominant dose-limiting toxic 
effects were reversible liver enzyme elevations, mostly in 
patients receiving BIBF 1120 doses above the MTD, and 
the most frequent AEs requiring dose adjustment or dis-
continuation were elevated liver enzymes, which were fully 
reversible and responded rapidly within 2 weeks of treatment 
discontinuation or dose reduction.
In patients who experienced nausea or vomiting, no dose 
reductions were necessary, without any differences between 
male and female patients. These kinds of side effects were 
treated with common antiemetic agents like metoclopramide, 
dimenhydrinate, or 5-HT3 receptor antagonist.
In all Phase II trials and in the Phase III ongoing trial, the 
squamous cell histology is not an exclusion criteria linked to 
the BIBF 1120: in the LUME-Lung 2 study, the nonsquamous 
histology is required by the selected chemotherapeutic agent, 
pemetrexed.
This is particularly important for patients with squamous 
cell NSCLC who are ineligible for treatment with bevaci-
zumab and who develop more grade 3 or 4 AEs than the 
adenocarcinoma patients in trials with other oral antiangio-
genic agents.
In this context, the potential use of BIBF 1120 in patients 
with squamous histology will be investigated as part of the 
BIBF 1120 + standard
docetaxel therapy
Placebo + standard
docetaxel therapy
BIBF 1120 + standard 
pemetrexed therapy
Placebo + standard
pemetrexed therapy
LUME-lung 1 LUME-lung 2
LUME-lung 1 and 2
Two large, multinational, randomized, double-blind, Phase III, placebo-controlled clinical trials 
assessing the efficacy of BIBF 1120 in combination with standard, second-line chemotherapy in 
patients with advanced or recurrent NSCLC
Patients with: 
• Histologically or cytologically confirmed NSCLC
• Stage IIIB/IV or recurrent NSCLC
• Failure of one previous first-line chemotherapy for advanced and/or metastatic disease
• Eligibility for docetaxel or pemetrexed therapy
Pivotal Phase III clinical trials
Figure 4 Phase III trials ongoing with BIBF 1120 in combination with chemotherapy: actually the LUME-Lung 1 trial stopped to recruit new patients, while the LUME-Lung 2 
is continuing recruitment. 
Abbreviation: NSCLC, non-small cell lung cancer.
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pivotal Phase III LUME-Lung 1 study, which will therefore 
provide more substantial data regarding the efficacy and 
safety of BIBF 1120 in this key patient population.
Due to its unique and multiple targeting profile, BIBF 
1120 has the potential to effectively prevent both tumor 
growth and dissemination, while also avoiding problems such 
as redundancy or resistance across the complex signaling 
networks. Clinical trials have demonstrated that, due to the 
non-CYP450-mediated metabolism of BIBF 1120, drug–drug 
interactions are not expected and, to date, no comedications 
have been excluded from BIBF 1120 trials.
This is of potential benefit both in considering combina-
tion with other cancer therapeutics and in taking into account 
medication being taken for comorbidities, which is a key 
issue for the majority of late-stage NSCLC patients. BIBF 
1120 showed comparable efficacy data to other angiogenesis 
inhibitors in similar patient populations.
The adequate selection of patients based on clinical 
factors and ECOG score should be considered the first and 
most important step to identify the most appropriate kind of 
patient population.
In line with Phase I and II trials, BIBF 1120 represents a 
new and very interesting alternative in the NSCLC treatment 
as a monotherapy or in combination with chemotherapeutic 
agents. Phase III trials are actually ongoing and they will 
clarify whether the combination with chemotherapeutic 
agents will be a feasible choice, and if the use of BIBF 1120 
will become part of a multimodality strategy with other 
targeted agents.
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